73 m2 (Table 1). Table 1 Patient baseline characteristics (n = 228) Age (years) 60.3 ± 11.5 Gender (male/female) 158 (69%)/70 (31%) BMI (kg/m2) 25.3 ± 4.4 Diabetes (n) 35 (15%) Dyslipidemia (n) 76 (33%) Heart disease (n) 8 (4%) CKD stage (n)  1 (eGFR ≥90) 23 (10%)  2 (60 ≤ eGFR < 90) 119 (52%)  3 (30 ≤ eGFR < 60) 70 (31%)  4 (15 ≤ eGFR < 30) 11 (5%) BMI body mass index, eGFR estimated glomerular filtration rate The baseline medications were monotherapy in 55%, dual therapy in 32% and therapy with 3 or more drugs in 13%. The majority of CDK inhibitor patients were taking ARBs (72%) or CCBs (54%), with only low numbers taking beta-blockers (6%), alpha-blockers (6%), Entospletinib in vitro or angiotensin converting enzyme inhibitors (ACE-I) (5%). At

the beginning of the study, almost half of the patients (48%) switched

from ARB to LOS/HCTZ, while 18% switched from CCB to LOS/HCTZ, 15% switched from ARB + CCB to LOS/HCTZ, and 20% switched to the prescriptions in which one of the pre-prescribed drugs was substituted by LOS/HCTZ. Changes in clinic and home BP Figure 1 shows the antihypertensive effect of LOS/HCTZ on clinic BP. After 6 months of switching from the baseline medications to LOS/HCTZ, R406 purchase significant decreases in clinic BP were observed in both systolic (145 ± 13 to 135 ± 15 mmHg) and diastolic BP (87 ± 9 to 81 ± 9 mmHg, both comparisons P < 0.001). The overall achieving rate of BP goal of either systolic BP less than 130 mmHg or diastolic BP less than 80 mmHg was 53% (120/228 cases). Fig. 1 Effect of LOS/HCTZ on clinic BP (all patients). Cyclooxygenase (COX) SBP systolic blood pressure, DBP diastolic blood pressure, LOS/HCTZ losartan/hydrochlorothiazide, ANOVA one-way analysis of variance Decreases

in the clinic systolic and diastolic BP were observed in all of the following 3 patterns (Fig. 2); patients switched from ARB to LOS/HCTZ (145 ± 12/88 ± 8 to 134 ± 12/80 ± 10 mmHg, both systolic and diastolic, P < 0.001); from CCB to LOS/HCTZ (147 ± 11/87 ± 10 to 134 ± /80 ± 10 mmHg, both systolic and diastolic, P < 0.001); and from ARB + CCB to LOS/HCTZ + CCB (140 ± 11/87 ± 11 to 131 ± 9/82 ± 9 mmHg, both systolic and diastolic, P < 0.001). Fig. 2 Effect of LOS/HCTZ on clinic BP (various switching patterns). SBP systolic blood pressure, DBP diastolic blood pressure, LOS/HCTZ losartan/hydrochlorothiazide, CCB Ca channel blockers, ANOVA one-way analysis of variance With respect to the difference of patients background classified by BP response, the responders defined as a reduction in systolic BP of ≥10 mmHg, had a greater systolic (responders, 150 ± 13 mmHg vs. non-responders, 140 ± 10 mmHg, P = 0.044) and diastolic BP (responders, 88 ± 9 mmHg vs. non-responders, 86 ± 10 mmHg, P = 0.041) at the entry of the trial. Figure 3 shows the results of home BP measurements. Morning BP was significantly decreased from 142 ± 12/87 ± 11 mmHg at baseline to 130 ± 17/80 ± 11 mmHg (both systolic and diastolic, P < 0.001).